Abstract:Background: Neurologic impediments occur in only 0.1% of Mycoplasma pneumoniae infections. Although direct intracerebral infection can occur in these patients, autoimmune-mediated reactions secondary to molecular mimicry are the most common pathophysiology of such neurological complications. These complications include immune-mediated encephalitis, peripheral neuritis such as Guillain-Barré syndrome, and many others. Miller Fisher syndrome is a one of the variants of Guillain-Barré syndrome that has been rarely linked to Mycoplasma pneumoniae infection. It is a condition classically characterized by the triad of ophthalmoplegia, areflexia, and ataxia. Most patients with Miller Fisher syndrome will have positive anti-ganglioside GQ1b antibodies found in their serum, making this autoantibody a very useful serological confirmation parameter. We report a case of a Miller Fisher syndrome in a woman with Mycoplasma pneumoniae infection. To the best of the authors' knowledge, such cases have been only rarely described in literature. Case presentation: A 35-year-old Chinese woman presented with sudden onset of double vision and ataxia 5 days after fever and mild flu symptoms. Her Mycoplasma pneumoniae antigen was positive with 1 over 2560 titer of total mycoplasma antibody and presence of immunoglobulin M antibody, suggesting acute infection, and her nerve conduction study revealed mild sensory axonal polyneuropathy with segmental demyelination. the Miller Fischer syndrome variant of Guillain-Barré syndrome secondary to Mycoplasma pneumonia was suspected and later confirmed by presence of serum anti-GQ1b autoantibody. She was treated with intravenous immunoglobulin 0.4 g/kg once daily for 5 days. Conclusions: The objective of this report is to share a case of an uncommon neurological complication of Mycoplasma pneumoniae infection, to increase the level of suspicion among clinicians that Miller Fischer syndrome can occur as an atypical presentation of an atypical pneumonia.

Miller Fisher syndrome following Pfizer COVID-19 vaccine

Course and Treatment of a Rare Neurological Sequelae After COVID-19: Miller Fisher Syndrome

COVID-19-Associated Miller Fisher Syndrome With Long Latency Period: A Case Report

A case report of thrombocytopenic COVID-19 and Miller–Fisher syndrome on a concurrent chronic immune neuropathy

Exploring Treatments for a Rare Guillain-Barré Variant: A Case Report of Miller-Fisher Syndrome

Ataxia and ophthalmoplegia: an atypical case of Miller Fisher syndrome (MFS) with anti-GAD antibody

[Miller-Fisher syndrome and the spectrum of oculomotor palsies with anti-GQ1b antibodies]

Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review

Bulbar Paralysis Associated with Miller-Fisher Syndrome and Its Overlaps in Chinese Patients

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

Unilateral Oculomotor Nerve Palsy Following Campylobacter Infection: A Mild Form of Miller Fisher Syndrome without Ataxia

Rehabilitation of a 51-Year-Old Patient With Miller Fisher Syndrome: A Case Report

Atypical presentation of an atypical pneumonia: a case report

Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome

Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases

Early-Onset Myasthenia Gravis Following COVID-19 Vaccination

Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination

Understanding the diagnostic challenges of Miller Fisher syndrome in children: a case report from an ophthalmological perspective

A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?

Guillain-Barré Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases

[A case of Fisher syndrome presented by rapidly progressing bilateral palatoplegia after cytomegalovirus infection]